CL2018000092A1 - Anticuerpos que se unen a la sortilina e inhiben la union de progranulina. - Google Patents

Anticuerpos que se unen a la sortilina e inhiben la union de progranulina.

Info

Publication number
CL2018000092A1
CL2018000092A1 CL2018000092A CL2018000092A CL2018000092A1 CL 2018000092 A1 CL2018000092 A1 CL 2018000092A1 CL 2018000092 A CL2018000092 A CL 2018000092A CL 2018000092 A CL2018000092 A CL 2018000092A CL 2018000092 A1 CL2018000092 A1 CL 2018000092A1
Authority
CL
Chile
Prior art keywords
antibodies
spellin
progranulin
union
bind
Prior art date
Application number
CL2018000092A
Other languages
English (en)
Spanish (es)
Inventor
Den Brink Edward Van
Ibrahim John Malik
Rønn Lars Christian Biilmann
Jeffrey B Stavenhagen
Søren Christensen
Jan Egebjerg
Arnout Gerritsen
Paul Parren
Jong Rob De
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CL2018000092A1 publication Critical patent/CL2018000092A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2018000092A 2015-07-13 2018-01-11 Anticuerpos que se unen a la sortilina e inhiben la union de progranulina. CL2018000092A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1512215.3A GB201512215D0 (en) 2015-07-13 2015-07-13 Agents,uses and methods

Publications (1)

Publication Number Publication Date
CL2018000092A1 true CL2018000092A1 (es) 2018-07-06

Family

ID=54013862

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2018000092A CL2018000092A1 (es) 2015-07-13 2018-01-11 Anticuerpos que se unen a la sortilina e inhiben la union de progranulina.
CL2020002468A CL2020002468A1 (es) 2015-07-13 2020-09-24 Anticuerpos que se unen a la sortilina e inhiben la union de progranulina.(divisional de solicitud 92-2018)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2020002468A CL2020002468A1 (es) 2015-07-13 2020-09-24 Anticuerpos que se unen a la sortilina e inhiben la union de progranulina.(divisional de solicitud 92-2018)

Country Status (35)

Country Link
US (6) US10479835B2 (cg-RX-API-DMAC7.html)
EP (1) EP3322726B1 (cg-RX-API-DMAC7.html)
JP (2) JP6979397B2 (cg-RX-API-DMAC7.html)
KR (1) KR102778576B1 (cg-RX-API-DMAC7.html)
CN (3) CN107849135A (cg-RX-API-DMAC7.html)
AR (1) AR105335A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016292980B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018000771A2 (cg-RX-API-DMAC7.html)
CA (1) CA2989739A1 (cg-RX-API-DMAC7.html)
CL (2) CL2018000092A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017012988A2 (cg-RX-API-DMAC7.html)
CR (1) CR20180002A (cg-RX-API-DMAC7.html)
DO (1) DOP2018000014A (cg-RX-API-DMAC7.html)
EA (1) EA201890038A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP18002725A (cg-RX-API-DMAC7.html)
ES (1) ES3024469T3 (cg-RX-API-DMAC7.html)
GB (1) GB201512215D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20250602T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071424T2 (cg-RX-API-DMAC7.html)
IL (1) IL256503B (cg-RX-API-DMAC7.html)
JO (1) JO3710B1 (cg-RX-API-DMAC7.html)
MA (1) MA42440B1 (cg-RX-API-DMAC7.html)
MX (1) MX2018000506A (cg-RX-API-DMAC7.html)
NI (1) NI201800007A (cg-RX-API-DMAC7.html)
PE (1) PE20181014A1 (cg-RX-API-DMAC7.html)
PH (1) PH12018500100A1 (cg-RX-API-DMAC7.html)
PL (1) PL3322726T3 (cg-RX-API-DMAC7.html)
RS (1) RS66856B1 (cg-RX-API-DMAC7.html)
RU (1) RU2735639C2 (cg-RX-API-DMAC7.html)
SV (1) SV2018005613A (cg-RX-API-DMAC7.html)
TN (1) TN2017000534A1 (cg-RX-API-DMAC7.html)
TW (1) TWI760305B (cg-RX-API-DMAC7.html)
UA (1) UA125136C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017009327A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201708613B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10849992B1 (en) 2015-04-07 2020-12-01 Alector Llc Methods of screening for sortilin binding antagonists
JP6999421B2 (ja) 2015-04-07 2022-02-04 アレクトル エルエルシー 抗ソルチリン抗体及びその使用方法
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) * 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
KR102530517B1 (ko) * 2018-07-13 2023-05-09 알렉터 엘엘씨 항-소틸린 항체 및 이들의 사용 방법
EP3666281A1 (en) * 2018-12-14 2020-06-17 Insusense ApS Compositions comprising sortilin-1
JP2023507846A (ja) * 2019-12-23 2023-02-27 デナリ セラピューティクス インコーポレイテッド プログラニュリン変異体
IL299329A (en) 2020-06-24 2023-02-01 Prothena Biosciences Ltd Antibodies recognizing sortilin
CN119403786A (zh) 2022-06-23 2025-02-07 德罗普尼尔生物有限公司 选择性诱导细胞外靶标在溶酶体中降解的双功能分子
CN118496354A (zh) * 2023-02-15 2024-08-16 三优生物医药(上海)有限公司 包含共同轻链的抗体库、其制备方法及其用途
WO2025031098A1 (zh) * 2023-08-09 2025-02-13 瑞诺元(苏州)生物科技有限公司 一种分拣蛋白1特异性的纳米抗体、含有其的重组aav及应用
WO2025132764A1 (en) * 2023-12-21 2025-06-26 Amylonix Ab A sortilin-binding polypeptide

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0486622B1 (en) 1989-08-09 1998-11-04 Rhomed, Incorporated Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5101990A (en) 1990-03-23 1992-04-07 Continental Pet Technologies, Inc. Stretch blow molded oblong or oval container
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
ES2146648T3 (es) 1993-03-09 2000-08-16 Genzyme Corp Procedimiento de aislamiento de proteinas de la leche.
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
IL144084A0 (en) 1999-02-03 2002-05-23 Biosante Pharmaceuticals Inc Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
CA2380813A1 (en) 1999-07-29 2001-02-08 Medarex, Inc. Human monoclonal antibodies to her2/neu
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
ES2380055T3 (es) 2002-12-20 2012-05-08 H. Lundbeck A/S Modulación de la actividad de neurotrofinas; método de escrutinio
EA016609B1 (ru) 2005-11-28 2012-06-29 Генмаб А/С Рекомбинантные моновалентные антитела и способы их получения
US20100028333A1 (en) 2006-12-15 2010-02-04 Getty Krista L Receptor for amyloid beta and uses thereof
SI3225251T1 (sl) 2006-12-21 2020-03-31 H. Lundbeck A/S Modulacija aktivnosti pronevrotrofinov
EP2185692A4 (en) 2007-08-10 2012-05-02 Medarex Inc HCO32 AND HCO27 AND RELATED EXAMPLES
JP5715045B2 (ja) 2008-04-27 2015-05-07 ハー・ルンドベック・アクチエゼルスカベット ソルチリンに対する特異的リガンドの設計
US8420784B2 (en) 2008-05-27 2013-04-16 Kyowa Hakko Kirin Co., Ltd. Interleukin 10 receptor, (IL-10R) antibodies
US20120039865A1 (en) 2008-08-19 2012-02-16 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
EP3165537A1 (en) 2008-12-19 2017-05-10 H. Lundbeck A/S Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders
RU2536232C2 (ru) * 2011-07-01 2014-12-20 Олег Ильич Эпштейн Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
US9822366B2 (en) 2012-11-02 2017-11-21 The Brigham And Women's Hospital, Inc. Sortilin 1 is a novel inducer of vascular calcification
JP6999421B2 (ja) 2015-04-07 2022-02-04 アレクトル エルエルシー 抗ソルチリン抗体及びその使用方法
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
KR102530517B1 (ko) 2018-07-13 2023-05-09 알렉터 엘엘씨 항-소틸린 항체 및 이들의 사용 방법

Also Published As

Publication number Publication date
KR20180030045A (ko) 2018-03-21
US20170267761A1 (en) 2017-09-21
US12331123B2 (en) 2025-06-17
TW201702273A (zh) 2017-01-16
PL3322726T3 (pl) 2025-06-23
CN114478774A (zh) 2022-05-13
IL256503A (en) 2018-02-28
HK1254356A1 (en) 2019-07-19
CO2017012988A2 (es) 2018-05-21
ECSP18002725A (es) 2018-03-31
GB201512215D0 (en) 2015-08-19
US20180305455A1 (en) 2018-10-25
MX2018000506A (es) 2018-05-11
AR105335A1 (es) 2017-09-27
US20250277040A1 (en) 2025-09-04
JP6979397B2 (ja) 2021-12-15
EP3322726C0 (en) 2025-03-12
ES3024469T3 (en) 2025-06-04
JO3710B1 (ar) 2021-01-31
EP3322726B1 (en) 2025-03-12
TWI760305B (zh) 2022-04-11
CN114478775A (zh) 2022-05-13
UA125136C2 (uk) 2022-01-19
US10428147B2 (en) 2019-10-01
NI201800007A (es) 2018-10-18
PE20181014A1 (es) 2018-06-26
US20200190188A1 (en) 2020-06-18
US10889650B2 (en) 2021-01-12
US20230159643A1 (en) 2023-05-25
SV2018005613A (es) 2018-02-23
TN2017000534A1 (en) 2019-04-12
MA42440A (fr) 2018-05-23
WO2017009327A1 (en) 2017-01-19
CN107849135A (zh) 2018-03-27
JP2022003058A (ja) 2022-01-11
HRP20250602T1 (hr) 2025-07-18
KR102778576B1 (ko) 2025-03-07
JP2018529635A (ja) 2018-10-11
ZA201708613B (en) 2021-03-31
HUE071424T2 (hu) 2025-08-28
IL256503B (en) 2022-02-01
AU2016292980B2 (en) 2022-10-06
CL2020002468A1 (es) 2021-01-29
AU2016292980A1 (en) 2018-01-18
PH12018500100A1 (en) 2018-07-30
EP3322726A1 (en) 2018-05-23
US20210269524A1 (en) 2021-09-02
CA2989739A1 (en) 2017-01-19
EA201890038A1 (ru) 2018-06-29
US10479835B2 (en) 2019-11-19
RU2018100824A3 (cg-RX-API-DMAC7.html) 2020-01-17
RU2735639C2 (ru) 2020-11-05
CR20180002A (es) 2018-04-09
MA42440B1 (fr) 2025-05-30
US11548950B2 (en) 2023-01-10
RS66856B1 (sr) 2025-06-30
DOP2018000014A (es) 2018-04-15
BR112018000771A2 (pt) 2018-09-25
RU2018100824A (ru) 2019-08-13

Similar Documents

Publication Publication Date Title
CL2018000092A1 (es) Anticuerpos que se unen a la sortilina e inhiben la union de progranulina.
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA202091540A1 (ru) Антитела к lilrb2
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201790173A1 (ru) Антитела, связывающие axl
MX2022005177A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
MD3360559T2 (ro) Compoziții conținând tulpini bacteriene
MX377710B (es) Anticuerpos monoclonales contra bcma.
MA40682B1 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
EA201691214A1 (ru) Антитела к cd33 и иммуноконъюгаты
EA201691488A1 (ru) Молекулы антител против pd-1 и их применения
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201790380A1 (ru) Ингибиторы mk2 и их применения
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
EA201791710A1 (ru) Антитела к транстиретину
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA201791711A1 (ru) Антитела к транстиретину
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
EA201791174A1 (ru) Антимикотическое соединение
EA201690383A1 (ru) НОВЫЕ АНТИТЕЛА К FC-γ-РЕЦЕПТОРУ IIB И ИХ ПРИМЕНЕНИЯ
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка